Adoptive Cell Therapy in Pediatric and Young Adult Solid Tumors: Current Status and Future Directions

John A. Ligon1,2*, Kristin M. Wessel1, Nirali N. Shah1 and John Glod1*

1 Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States, 2 Department of Pediatrics, Division of Hematology/Oncology, University of Florida College of Medicine, Gainesville, FL, United States

Advances from novel adoptive cellular therapies have yet to be fully realized for the treatment of children and young adults with solid tumors. This review discusses the strategies and preliminary results, including T-cell, NK-cell and myeloid cell-based therapies. While each of these approaches have shown some early promise, there remain challenges. These include poor trafficking to the tumor as well as a hostile tumor microenvironment with numerous immunosuppressive mechanisms which result in exhaustion of cellular therapies. We then turn our attention to new strategies proposed to address these challenges including novel clinical trials that are ongoing and in development.

Keywords: adoptive cell immunotherapy, solid tumor, tumor microenvironment, immune evasion, CAR (chimeric antigen receptor)

INTRODUCTION

Immunologically “hot” solid tumors (e.g. melanoma) (1) with a tumor microenvironment (TME) marked by infiltrating CD8+ T-cells (2, 3), high programmed death ligand 1 (PD-L1) expression (4), or a high tumor mutational burden have shown remarkable responses to immunotherapy including immune checkpoint inhibitors (ICIs) (5). Unfortunately, these benefits have not extended to “cold” tumors (e.g. prostate or pancreatic cancer) (1) where T-cells are either entirely absent (“immune desert”) or sequestered at the periphery (“immune-excluded”) (3, 6). Many pediatric/adolescent and young adult solid tumors are cold tumors (7, 8) and have failed to respond to ICIs (9).

Several approaches have attempted to harness cellular therapy to cure these tumors. Autologous hematopoietic stem cell transplant (HSCT) has enabled maximal chemotherapy dosing in susceptible tumors with varying levels of effectiveness in neuroblastoma (10), Ewing sarcoma (11), breast cancer (12), retinoblastoma (13), hepatoblastoma (14), and other diseases. Recently some groups have piloted allogeneic HSCT to treat solid tumors. Though durable responses are rare, evidence for graft-vs-tumor effect has been observed (15). Finally, as adoptive cellular therapy (ACT) has proven transformative for leukemia and lymphoma, the development of novel ACT for
solid tumors has exploded (Figure 1). In this review, we discuss ACT in solid tumors in clinical development, consider challenges plaguing the field, and highlight proposed strategies which will be tested in future clinical trials.

**T-CELL BASED THERAPIES**

T-cells are critical in immune surveillance for cancer. The T-cell receptor (TCR) can recognize cancer-specific antigens processed by major histocompatibility complex (MHC) and presented on the cell surface. TCR engagement by MHC-presented non-self antigens leads to activation and T-cell mediated killing (16). T-cell cytotoxicity in solid tumors has been leveraged using both native T-cells and autologous T-cells genetically engineered to express a specific TCR. Future efforts in allogeneic “off-the-shelf” approaches are being actively studied.

**Tumor Infiltrating Lymphocytes (TILs)**

Early studies demonstrated that heterogeneous tumor infiltrating lymphocytes (TILs) collected from a freshly-resected tumor and expanded in vitro were able to specifically lyse autologous tumor (17). Subsequent clinical investigations showed transient responses in patients with metastatic melanoma after TIL infusion, typically under high IL-2 conditions (17). Early TIL trials reported responses in 49-72% of patients with melanoma (18, 19). Pretreatment with lymphodepleting chemotherapy led to improved TIL persistence (18) and recent advances include selection of TILs that recognize patient-specific tumor antigens using single cell sequencing (20). Selected autologous TILs have shown activity in several epithelial malignancies (21, 22).

While advances using TILs continue, the inability to isolate and effectively expand TILs from some solid tumors remains a challenge.

**Engineered TCR-Based ACT**

Initial attempts at engineering T-cells for ACT concentrated on genetic engineering of specific TCRs into autologous T-cells collected via peripheral blood apheresis with subsequent reinfusion. Expression of cancer/testis antigens (CTAs) including melanoma antigen gene (MAGE) family proteins, synovial sarcoma X breakpoint (SSX) family proteins, and New York esophageal squamous cell carcinoma (NY-ESO-1) is normally restricted to the germline. However, solid tumors including melanoma, SS, myxoid/round cell liposarcoma (MRCL), and osteosarcoma express CTAs. Robbins and colleagues targeted NY-ESO-1 using a transduced TCR recognizing the peptide epitope SLLMWITQC in the context of HLA-A*02. Transgenic T-cells combined with IL-2 following lymphodepletion led to responses in 5/11 patients with SS and 2/11 patients with melanoma (23). A subsequent study showed responses in 6/12 patients with NY-ESO-1+ SS in an initial cohort (24), with one complete response (CR) and 14 partial responses (PR) in the first 42 patients (25). This response rate represents a potentially significant improvement over previous therapies for SS (26). These T-cells maintained clonal diversity over time and persisting cells were primarily of central memory.

---

![Figure 1](image_url)  
**FIGURE 1** | Multiple cell types available to engineer for adoptive cellular therapy. Myeloid cells, NK cells, and T-cell-based therapies each have advantages and disadvantages which should be considered within the context of the histology to be targeted.
and stem cell memory populations (24). Ongoing trials are further investigating genetically engineered NY-ESO-1 targeting autologous T-cells in solid tumors including SS, MRCL and non-small cell lung cancer (NCT02992743, NCT03967223, NCT03709706).

Other successfully targeted CTAs include MAGE-A3 and MAGE-A4. Seventeen patients were treated in a dose escalation study of autologous T-cells genetically modified to express an MHC class II-restricted TCR recognizing MAGE-A3 combined with IL-2 (27). One patient with cervical cancer had a CR and several PRs were observed in patients with esophageal cancer, urothelial cancer, and osteosarcoma. Despite encouraging responses, the significant neurotoxicity observed in this and a subsequent trial targeting MAGE-A3 has hampered development of this strategy (28). In a phase I trial of a TCR developed in a transgenic murine model and recognizing residues 112-120 (KVAELVHFL) of MAGE-A3, 3/9 patients developed significant neurotoxicity (29). Preliminary data for the SURPASS trial utilizing autologous T-cells transduced with a MAGE-A4 TCR and CD8a co-receptor reported 2/5 patients with PRs (30). A MAGE-A4 targeting TCR is also being evaluated in a phase II study for patients with SS and MRCL (NCT04044768). Additional TCR-based strategies targeting CTAs are in development (31).

Viral antigens have also been successfully targeted for treating solid tumors using ACT. TILs targeting human papillomavirus (HPV) antigens E6 and E7 have shown efficacy in early phase clinical trials in HPV-associated carcinomas with responses in 5/18 patients with cervical cancer and 2/11 with head and neck cancer (32). Subsequent work identified TCRs recognizing epitopes of HPV16 E6 and E7 in the context of HLA-A*02:01 and T-cells genetically engineered to express these TCRs led to responses in two early phase studies (33, 34). Epstein-Barr virus (EBV) is associated with several solid tumors (e.g., nasopharyngeal carcinoma [NPC] and post-transplant lymphoproliferative disorder [PTLD]). EBV-specific cytotoxic T-lymphocytes (CTLs) were tested to treat PTLD following HSCT (35). EBV-specific CTLs resulted in PR for 2/10 patients with EBV-associated NPC (36). A phase 3 trial comparing chemotherapy with EBV-specific CTLs combined with chemotherapy for NPC is underway (NCT02578641). TCR-based therapy has also been explored for Merkel cell carcinoma, a skin cancer associated with Merkel cell polyomavirus (37). Autologous T-cells with TCRs recognizing an epitope of Merkel cell polyomavirus, large T antigen and small T antigen, led to durable regression of metastatic lesions in several patients (38).

**CART-Based ACT**

HLA-restriction (limiting patient access) and reliance on tumor MHC expression have limited TCR-based therapy utility. Chimeric antigen receptor T-cells (CAR) are autologous T-cells engineered ex vivo to enable MHC-independent tumor cell killing without HLA restriction. First-generation CAR have 3 components: a specific antibody-derived single chain variable fragment (scFv), a hinge/transmembrane domain, and a T-cell signaling (CD3ζ) domain. Second-generation CAR incorporate one additional co-stimulatory domain, while third-generation CAR incorporate 2 additional co-stimulatory domains. Fourth-generation CAR, also known as TRUCKs (T cells redirected for antigen unrestricted cytokine-initiated killing) include a CAR-inducible transgene product, often pro-inflammatory cytokines which may enhance CART cytotoxicity and activate other immune cells in an immunosuppressive TME (39).

Human epidermal growth factor receptor 2 (HER2) is expressed on several solid tumor types and has attracted interest as a CART target. A clinical trial utilizing 10^8/m^2 of a third-generation CART incorporating a scFV derived from the humanized monoclonal antibody trastuzumab following lymphodepletion for HER2+ solid tumors. A patient with metastatic colorectal cancer developed fatal respiratory failure 15 minutes after CART infusion. This was thought to be due to massive cytokine release upon recognition of HER2 at low levels on lung epithelium and prompted concerns about the safety of HER2-CART (40). A subsequent HER2-CART trial in HER2+ sarcomas instead utilized the FRP5 scFV, omitted lymphodepletion, and selected a lower starting dose of 10^6/m^2. There were no dose-limiting toxicities, but also no CART expansion. Doses greater than 10^6/m^2 were associated with greater persistence. 4/17 evaluable patients had stable disease and 1 patient had a PR after a second CART infusion (41). To improve CART expansion and persistence, an ongoing phase 1 HER2-CART trial (NCT00902044) has incorporated lymphodepletion and HER2-CART doses up to 10^8/m^2. Thus far two CRs have been reported (42, 43).

Clinical experience with CART targeting the dianganglioside GD2, which is highly expressed on osteosarcoma, neuroblastoma, and many central nervous system (CNS) tumors, also suggests that lymphodepletion and adequate cell dose are important for CART expansion and persistence. A phase 1 trial utilizing first-generation GD2-CART without lymphodepletion in neuroblastoma demonstrated safety and clinical activity with 3 CRs, but showed limited expansion and persistence (44, 45). A subsequent trial (NCT02107963) utilized a third-generation GD2-CART with lymphodepletion, and demonstrated good expansion (46). A phase I study of a third-generation GD2-CART with or without lymphodepletion in relapsed/refractory neuroblastoma showed increased CART expansion following lymphodepletion (47). A phase I trial utilizing escalating doses of a second-generation GD2-CART with lymphodepletion of varying intensity in relapsed/refractory neuroblastoma showed regression of soft tissue and bone marrow disease following CART doses of at least 10^7/m^2 (48). GD2-CART have shown promising clinical activity in a phase 1 trial in H3K27M+ diffuse midline gliomas, which are universally fatal malignancies (NCT04196413) (49). Based on preclinical data suggesting that incorporation of IL-15 into CART further enhances persistence and cytotoxicity (50, 51), ongoing trials are utilizing GD2-CART and GD2-CAR-NKT cells engineered to express IL-15 (NCT03721068, NCT03294954).

The checkpoint molecule B7-H3(CD276) is another CART target of interest given its high expression on multiple solid tumor types. Preclinical studies have demonstrated encouraging activity of B7-H3-CART in various xenograft models (52–54). Clinical trials utilizing B7-H3-CART are underway in pediatric...
and adult solid tumors (NCT04897321, NCT04483778, NCT04432649, NCT05211557, NCT04670068) and CNS tumors (NCT04185038, NCT04385173, NCT04077866).

**TRuC**™-**T**-Cell Based ACT

TCR fusion constructs (TRuCs) also enable HLA-independent cell killing. In contrast to CART, which incorporate only the intracellular signaling domain of the CD3ζ chain, TRuCs involve fusion of the scFv to the N-terminus of any of the other five subunits in the TCR complex. TRuCs are incorporated into the TCR on translation, engage the TCR complex upon activation, and are efficacious in solid tumor xenograft models (55). Anti-mesothelin TRuCs are being studied in a phase 1/2 clinical trial (NCT03907852) with preliminary evidence of activity, with 3/7 patients (2 with mesothelioma, 1 with ovarian cancer) achieving a PR (56).

**NK-CELLS**

NK-cells are innate immune cells and protect against infections and cancer (57, 58). Efforts to harness NK-cell biology for ACT in cancer treatment has gained considerable interest as an alternative to T-cell based immunotherapeutics. NK-cells possess qualities which may allow them to overcome the hostile TME (58–60). While T-cells recognize unique tumor antigens, NK-cell-mediated cytotoxicity depends on the sum of activating and inhibitory signals, including tumor cell lack of MHC class 1 expression or antibody-dependent cell-mediated cytotoxicity (61). Furthermore, NK-cells can produce inflammatory cytokines such as IFNγ and TNFα which can activate CD8+ TILs and enhance their cytotoxicity (62).

These properties allow NK-cells to be engineered or manipulated via different mechanisms from T-cell-centric immunotherapies. Examples include the administration of agonist cytokines or engineering NK-cells which constitutively secrete these cytokines (63). Others have proposed NK-cells which constitutively secrete chemotactic factors to recruit cytotoxic lymphocytes to the TME (64). Tri-specific NK-cell engagers (TriKEs) have been proposed to confer tumor-specificity to NK-cells and enhance NK-cell activation by engaging stimulatory receptors such as the IL-15 receptor (65, 66). Additionally, CAR NK-cells (CAR-NK) designed from stem cell progenitors represent another way to generate tumor-specific NK-cells. Attractively, CAR-NK may be less toxic and could be produced at lower cost than CART (67). Recent experience with CD19-CAR-NK in B-cell malignancies provides proof-of-concept that this strategy can be safely and effectively utilized and with potential for persistence (68). Barriers remain to production and monitoring of persistence of these cells, but additional alterations to the NK-cell product and manufacturing strategies have been proposed to mitigate these issues. Finally, NK-cells also express immune checkpoint molecules such as PD-1, and either combination with ICIs or intrinsic downregulation of these checkpoint molecules have been proposed as mechanisms to further enhance the efficacy of NK-cell-based approaches (69, 70).

**MYELOID CELL THERAPIES**

Myeloid cells readily infiltrate primary tumors and metastases. Harnessing this property for ACT shows promise in the treatment of solid malignancies (71). Myeloid cells are highly plastic and may acquire a wide spectrum of immune-stimulatory or immune-suppressive phenotypes in response to the local milieu. Tumor associated macrophages (TAMs) are polarized to an anti-tumor M1 phenotype in response to pro-inflammatory factors such as IFNγ, GM-CSF and lipopolysaccharide. M1 TAMs promote Th1 responses, phagocytosis of tumor cells, and antigen presentation. Tumor-associated cytokines such as IL-10, IL-4, IL-13 and TGF-β promote polarization towards an immunosuppressive M2 phenotype. M2 TAMs promote tumor progression through mechanisms including angiogenesis, extracellular matrix (ECM) remodeling and regulatory T-cell recruitment (72). This M1/M2 classification is an oversimplification, however induction of an M1-like, anti-tumor phenotype is important for the success of myeloid-based ACT. The first myeloid-based ACT utilized macrophages polarized to the M1 phenotype ex vivo with IFNγ. Clinical trials showed limited efficacy, but these therapies were generally well-tolerated (73–75).

Subsequent work has focused on engineering myeloid cells towards a more potent and durable anti-tumor phenotype. Anti-HER2 CAR-macrophages (CARM) reduced tumor growth and prolonged survival while reprogramming the immune-suppressive TME in xenograft models (76). A first-in-human trial evaluating CARM is now underway in HER2-overexpressing solid tumors (NCT04660929). Preclinical work has shown that myeloid cells can also be used to deliver cargo to the TME. Administration of myeloid cells genetically engineered to express IL-12, a potent anti-tumor cytokine, resulted in durable cures in a syngeneic model of embryonal rhabdomyosarcoma through activation of T-cell responses in the tumor and metastatic microenvironment (77).

**CHALLENGES IN SOLID TUMOR ACT**

Significant remaining challenges for optimization of solid tumor ACT are outlined in this section. Additionally, we will summarize proposed strategies to overcome these challenges (Figure 2).

Selection of antigens such as GD2 (78) and CTAs (79), which are expressed on numerous solid tumors, leverages the possibility that a single ACT could be active across multiple histologies. However, few antigens are tumor-specific. Thus, identifying a target antigen which will allow tumor clearance without unacceptable normal tissue toxicity (on-target/off-tumor effect) is problematic. In addition to selecting the proper target antigen, low antigen density and antigen downregulation within heterogeneous solid TMEs have emerged as additional barriers to ACT (80, 81).

ACT trafficking is also challenging in solid tumors. Trafficking can be inhibited by physical barriers, loss of MHC class I expression, repellent cytokine gradients, expression of inhibitory ligands such as PD-L1, and abnormal tumor vasculature (82). CNS tumors are further shielded by the
blood-brain barrier (83). If ACTs cannot traffic to the tumor and engage their target antigen, they fail to be activated and expand, leading to rapid loss of ACT.

Finally, the TME present in many solid tumors is hostile to the ACT. Tumors recruit immunosuppressive TAMs and myeloid-derived suppressor cells (MDSCs) (84) which express inhibitory molecules such as PD-L1 (84), secrete inactivating cytokines such as IL-10 (85), and promote a hypoxic TME (86) which can thwart ACT cytotoxicity. These tumor-sustaining programs promote rapid and irreversible ACT exhaustion, inhibit expansion, and result in failure of tumor clearance. Further ACT engineering or combination with agents to allow ACTs to overcome these challenges, will be necessary for ACT optimization in solid tumors.

**DISCUSSION: OVERCOMING THE IMMUNE-SUPPRESSIVE TME IN ACT FOR SOLID TUMORS**

Aberrant tumor vasculature and ECM deposition impede ACT trafficking. Regional ACT administration is one strategy to overcome this hurdle. A recent phase I trial demonstrated that intrapleural administration of mesothelin-CART combined with pembrolizumab was safe and feasible, and showed potential efficacy with 2 patients demonstrating metabolic CR on PET scan (87). Intraventricular CART administration for both primary brain tumors and CNS metastases is also under evaluation in early-phase clinical trials and in preclinical models (88, 89) (NCT04196413). Additionally, methods to disrupt the blood-brain barrier to allow trafficking of ACT to CNS tumors, such as focused ultrasound (90) or other mechanical or pharmacological methods (91) have been piloted.

Further genetic modification of ACTs to overcome and leverage features of the hostile TME is currently being explored. Many solid tumor types recruit TAMs by producing chemokines such as CXCL8 and CXCL2. Preclinical data suggest that chemokine secretion can be leveraged to enhance CART trafficking by engineering CART to express chemokine receptors. For example, CXCR2-modified GPC3-CART had improved trafficking in a hepatocellular carcinoma model (92), while a CXCR1/2-modified CD70-CART enhanced CART trafficking and efficacy in murine GBM, ovarian cancer and pancreatic cancer models (93). Many groups have also sought to generate a more “fit” ACT through enhanced cytokine secretion.
in the TME makes them an attractive therapeutic target. Additional modifications include creation of ACT which is resistant to exhaustion [e.g. DNA methyltransferase 3 alpha knock-out (95) or PD-1 deletion (96)] or tuning ACT to be effective despite low antigen density [e.g. c-Jun overexpression (97, 98)]. These modifications of ACTs are now entering clinical trials [e.g. TGF-βR knockout CART NCT04976218].

Tumor-associated vasculature is characterized by pericyte loss, resulting in leakage and adhesion molecule down-regulation impairing T-cell migration into the tumor (99). VEGF inhibitors, which promote vascular normalization, may enhance CD8+ T-cell infiltration into tumors (100). Anti-VEGF agents have shown synergy with ICIs in select solid malignancies, resulting in FDA approval of these combinations in hepatocellular carcinoma and renal cell carcinoma (101). Preclinical studies suggest that antiangiogenics can also improve ACT trafficking (102, 103). Combining ACTs with antiangiogenics warrants further study in clinical trials.

ECM-remodeling agents may enhance the ability of ACTs to infiltrate tumors. In gastric cancer models, hyaluronic acid reduced mesothelin-CART infiltration, however these CART had superior efficacy when combined with infusion of a secreted form of the human hyaluronidase PH20 (104). CART engineered to express heparinase, which degrades heparan sulfate proteoglycans, showed superior anti-tumor activity and were associated with increased T-cell infiltration in preclinical models (105).

The solid TME contributes to T-cell exhaustion via multiple mechanisms, including repeated TCR stimulation and metabolic stress, thereby reducing the ACT efficacy. Engineering CART to reduce tonic signaling through incorporation of the 4-1BB costimulatory domain vs CD28 costimulatory domain showed reduction in CART exhaustion and enhanced persistence and efficacy in preclinical studies (106). Induction of transient rest periods in CART, such as by dasatinib utilization, has shown exhaustion reversal and improved efficacy (107). A dasatinib-containing culture platform is being used to manufacture GD2-CART in ongoing clinical trials (NCT04539366, NCT04196413). CART combination with ICIs is also under evaluation in clinical trials (108).

The ability of myeloid cells to orchestrate immune responses in the TME makes them an attractive therapeutic target. Low-dose chemotherapy has shown reduction of tumor MDSCs (109–111). MDSC differentiation with ATRA reduced their immune-suppressive function and enhanced efficacy of GD2-CART in preclinical models (112). In a pilot trial studying ipilimumab vs ipilimumab combined with ATRA, patients receiving ATRA had fewer circulating MDSCs (113). Inhibiting myeloid cell trafficking through CSF1R inhibition is another potential avenue to reduce myeloid cell immune-suppression in the TME. CSF1R-targeting agents are generally well-tolerated in the clinic, and the multi-TKI CSF1R inhibitor Pexidartinib is FDA-approved to treat tenosynovial giant-cell tumor (114, 115). Clinical trials studying CSF1R inhibitors with ICIs are underway (NCT02777710, NCT02829723, NCT03502330, NCT04848116, NCT02526017).

CONCLUSION

While ACT has yet to yield the transformative results in solid tumors that CART have shown for hematologic malignancies, evidence exists that some patients with solid tumors may respond to ACT. T-cells, NK-cells, and myeloid cells have each been engineered to target these tumors, and each have advantages and unique challenges. Further engineering ACTs to overcome tumor immune resistance mechanisms and better understanding how to combine with TME-modifying agents will be critical to expanding the number of patients with solid tumors who may derive therapeutic benefit.

AUTHOR CONTRIBUTIONS

JL, KW, and JG wrote the first version of the manuscript. NS provided critical feedback and additions. All authors contributed to the final version of the manuscript.

ACKNOWLEDGMENTS

This work was supported in part by the Intramural Research Program, Center of Cancer Research, National Cancer Institute. We appreciate the contributions of Erina He and the NIH Medical Arts team in aiding in the production of the figures for this manuscript.

REFERENCES

1. Maleki Vareki S. High and Low Mutational Burden Tumors Versus Immunologically Hot and Cold Tumors and Response to Immune Checkpoint Inhibitors. J Immunother Cancer (2018) 6:1357. doi: 10.1186/s40425-018-0479-7
2. Ayers M, Lunceford J, Nebozyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-Gamma-Related mRNA Profiles Predict Clinical Response to PD-1 Blockade. J Clin Invest (2017) 127:2930–40. doi: 10.1172/JCI91190
3. Hegle PS, Karanikas V, Evers 5. T. The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. Clin Cancer Res (2016) 22:1865–74. doi: 10.1158/1078-0432.CCR-15-1507
4. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Cosset T, Fulop A, et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J Clin Oncol (2019) 37:5373–46. doi: 10.1200/JCO.19.00149
5. Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor Mutational Load Predicts Survival After Immunotherapy Across Multiple Cancer Types. Nat Genet (2019) 51:202–6. doi: 10.1038/s41588-018-0312-8
6. Jerby-Aroni L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, et al. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell (2018) 175:984–997.e24. doi: 10.1016/j.cell.2018.09.006
7. Chen L, Oke T, Siegel N, Cojocaru G, Tam AJ, Brosser RL, et al. The Immunosuppressive Niche of Soft-Tissue Sarcomas Is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures. Clin Cancer Res (2020) 26:4018–30. doi: 10.1158/1078-0432.CCR-19-3416
Ligon et al. Solid Tumor Adoptive Cell Therapy

8. Ligon JA, Choi W, Cojocaru G, Fu W, Hisue EH, Oke TF, et al. Pathways of Immune Exclusion in Metastatic Osteosarcoma Are Associated With Inferior Patient Outcomes. J Immunother Cancer 2019; 7(9):e001772. doi: 10.1136/jitc-2020-001772

9. Davis KL, Fox E, Merchant MS, Reid JM, Kudgus RA, Liu X, et al. Nivolumab in Children and Young Adults With Relapsed or Refractory Solid Tumors or Lymphoma (ADVL1412): A Multicentre, Open-Label, Single-Arm, Phase 1-2 Trial. Lancet Oncol 2020; 21:541–50. doi: 10.1016/S1470-2045(20)30023-1

10. Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, et al. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. JAMA 2019; 322:746–55. doi: 10.1001/jama.2019.11642

11. Ladenstein R, Potschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, et al. Primary Disseminated Multifocal Ewing Sarcoma: Results of the EuroEWING 99 Trial. J Clin Oncol (2010) 28:3284–91. doi: 10.1200/JCO.2009.22.9864

12. Pedrazzoli P, Martino M, Delfanti S, Generali D, Rosti G, Bregni M, et al. Efficacy and Long-Term Safety of Nivolumab in Trilateral Retinoblastoma: A Systematic Review and Meta-Analysis. Lancet Oncol (2014) 15:1157–67. doi: 10.1016/S1470-2045(14)70336-5

13. de Jong MC, Kors WA, de Graaf P, Castelijns JA, Kivela T, Moll AC. Improving Outcome. Results of the GPOH Study Hb99. With Autologous Stem Cell Transplantation in Hepatoblastoma Does Not Improve Outcome. Results of the GPOH Study HB99. Klin Padiatr (2019) 231:283–90. doi: 10.1055/a-1014-3250

14. Llosa NJ, Cooke KR, Chen AR, Gamper CJ, Klein OR, Zambidis ET, et al. Antitumor Activity Associated With Prolonged Persistence of Adoptively Transferred NY-ESO-1 (C259) T Cells in Synovial Sarcoma. Clin Cancer Res (2014) 20:651–68. doi: 10.1158/1078-0432.CCR-13-2708

15. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in Patients With Metastatic Melanoma. A Preliminary Report. N Engl J Med 1988; 319:1676–80. doi: 10.1056/NEJM198812223192527

16. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens. J Clin Oncol (2008) 26:5233–9. doi: 10.1200/JCO.2008.15.5449

17. Rosenberg SA, Dudley ME, Adoptive Cell Therapy for the Treatment of Patients With Metastatic Malignancy. Curr Opin Immunol (2009) 21:233–40. doi: 10.1016/j.coi.2009.03.002

18. Yamamoto TN, Kishoton RJ, Restifo NP. Developing Neoantigen-Targeted T Cell-Based Treatments for Solid Tumors. Nat Med (2019) 25:1488–99. doi: 10.1038/s41591-019-0596-y

19. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, et al. Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient With Epithelial Cancer. Science (2014) 344:641–5. doi: 10.1126/science.1251102

20. Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, et al. Regression of Metastatic Merkel Cell Carcinoma Following Transfer of TRICR T Cells for Cancer Treatment: Achievements, Hurdles, and Goals. Front Immunol (2020) 2011:1689. doi: 10.3389/fimmu.2020.01689

21. Hong D, Clarke J, Johanss T, Kebriaei P, Meyham J, Galal A, et al. Initial Safety, Efficacy, and Product Attributes From the Surpass Trial With ADP-A243CD8, A SPEAR T-Cell Therapy Incorporating an Affinity Optimized TCR Targeting MAGE-A4 and a CD8(a) Alpha Co-Receptor. J Immunother Cancer (2020) 8:A231–1. doi: 10.1116/2013-SITC2020.0379

22. Martin AD, Wang X, Sandberg ML, Negri KR, Wu ML, Toledo Warshaviak D, et al. Re-Examination of MAGE-A3 as a T-Cell Therapeutic Target. J Immunother Cancer (2021) 4:95–105. doi: 10.1007/1078-0432.CCR-18-2722

23. Norberg S, Nagarsheth N, Sinkoe A, Adhikary S, Meyer T, Lack J, et al. Safety and Clinical Activity of Gene-Engineered T-Cell Therapy Targeting HPV-16 E7 for Epithelial Cancers. J Clin Oncol (2020) 38. doi: 10.1200/JCO.2019.38.15_suppl.101

24. Chapman AG, Afanasev OK, Iyer JG, Paulson KG, Parvathaneni U, Wang J, et al. Regression of Metastatic Merkel Cell Carcinoma Following Transfer of Polyomavirus-Specific T Cells and Vaccines Capable of Re-Inducing HLA Class-I. Cancer Immunol Res 2014; 2:27–36. doi: 10.1158/2326-6066.CIR-13-0087

25. Shahma S, Leung WK, Kesel HE. Virus-Specific T Cells for Malignancies - Then, Now and Where to? Curr Stem Cell Rep (2020) 6:17–29. doi: 10.1007/issn-020-00170-6

26. Ahmed N, Bawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, et al. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Solid Tumors. J Clin Oncol (2015) 33:1688–96. doi: 10.1200/JCO.2014.58.0225

27. Hegde M, Joseph SK, Pashankar F, DellReno C, Sanber K, Navi S, et al. Tumor Response and Endogenous Immune Reactivity After Administration of HER2 CAR T Cells in a Child With Metastatic Rhabdomyosarcoma. Nat Commun (2020) 11:3549. doi: 10.1038/s41467-020-17175-8
43. Derenzo C, Navai SA, Joseph S, Samber K, Byrd T, Zhang H, et al. Administration of HER2-CAR T Cells After Lymphodepleting Safety Inducing T Cell Expansion and Induces Clinical Responses in Patients With Advanced Sarcomas. Atlanta, GA: 110th Annual Meeting of the American Association for Cancer Research (2019).

44. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al. Virus-Specific T Cells Engineered to Coexpress Tumor-Specific Receptors: Persistence and Antitumor Activity in Individuals With Neuroblastoma. *Nat Med* (2008) 14:2164–70. doi: 10.1038/nm.1882

45. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor Activity and Long-Term Fate of Chimeric Antigen Receptor-Positive T Cells in Patients With Neuroblastoma. *Blood* (2011) 118:6050–6. doi: 10.1182/ blood-2011-05-35597

46. Stronck D, Lee DW, Ren J, Sahatino M, Highfill S, Khuhu H, et al. Elutriated Lymphocytes for Manufacturing Chimeric Antigen Receptor T Cells. *J Transl Med* (2017) 15:59. doi: 10.1186/s12967-017-1160-5

47. Hecezy A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, et al. CAR T Cells Administered in Combination With Lymphodepletion and PD-1 Inhibition to Patients With Neuroblastoma. *Mol Ther* (2017) 25:2214–24. doi: 10.1016/j.ymthe.2017.05.012

48. Straathof K, Flutterm B, Jain N, Loka T, Depani S, et al. Antitumor Activity Without on-Target Off-Tumor Toxicity of GD2-Chimeric Antigen Receptor T Cells in Patients With Neuroblastoma. *Sci Transl Med* (2020) 12(575):eabb1169. doi: 10.1126/scitranslmed.abb1169

49. Majzner R, Ramakrishna S, Mochizuki A, Patel S, Chinnasamy H, Yeom K, et al. EPCT-14. GD2 CAR T-Cells Mediate Clinical Activity And Manageable Toxicity In Children And Young Adults With H3K27M-Mutated DIPG And Spinal Cord DMG. *Neuro-Oncology* (2021) 23:449–50. doi: 10.1093/neuonc/noab090.200

50. Chen Y, Sun C, Landoni E, Metelitsa L, Dotti G, Savoldo B. Eradication of Neuroblastoma by T Cells Redirected With an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15. *Clin Cancer Res* (2019) 25:2915–24. doi: 10.1158/1078-0432.CCR-18-1811

51. Xu X, Huang W, Hecezy A, Liu D, Guo L, Wood M, et al. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity Against Neuroblastoma. *Clin Cancer Res* (2019) 25:7126–38. doi: 10.1158/1078-0432.CCR-19-0421

52. Majzner RG, Theruvath JL, Nellau A, Heitzenneder S, Cui Y, Mount CW, et al. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. *Clin Cancer Res* (2019) 25:2560–74. doi: 10.1158/1078-0432.CCR-18-0432

53. Theruvath J, Sotillo E, Mount CW, Graef CM, Delaidelli A, Heitzenneder S, et al. Locirocetn (2020): B7-H3-Targeted CAR T Cells for Treatment of Atypical Teratoid/Rhabdoid Tumors. *Nat Med* (2020) 26:712–9. doi: 10.1038/s41591-020-0821-8

54. Du H, Hirabayashi K, Ahn S, Kren NP, Montgomery SA, Wang X, et al. Antitumor Responses in the Absence of Toxicity in Solid Tumors By Targeting B7-H3 via Chimeric Antigen Receptor T Cells. *Cancer Cell* (2019) 35:221–237 e8. doi: 10.1016/j.ccell.2019.01.002

55. Baeuerle PA, Ding J, Patel E, Thorausch N, Horton H, Gierut J, et al. Synthetic TRuC Receptors Engaging the Complete T Cell Receptor for Potent Anti-Tumor Response. *Nat Commun* (2019) 10:2087. doi: 10.1038/ s41467-019-10097-0

56. Hong DS, Johnson M, Tanyi JL, MacMullen L, Tighe R, Jalbert L, et al. Targeting B7-H3 via Combined Antibody and Cytokine Therapy Primes Tumors for Elimination by Checkpoint Blockade. *Cell Rep* (2021) 37:110021. doi: 10.1016/j.celrep.2021.110021

57. Kim N, Kim HS. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells. *Front Immunol* (2018) 9:2041. doi: 10.3389/fimmu.2018.02041

58. Anderson NR, Minutolo NG, Gill S, Klischinsky M. Macrophage-Based Approaches for Cancer Immunotherapy. *Cancer Res* (2021) 81:1201–8. doi: 10.1158/0008-5472.CAN-20-2990

59. Koo J, Hayashi M, Verneris MR, Lee-Sherick AB. Targeting Tumor-Associated Macrophages in the Pediatric Sarcoma Tumor Microenvironment. *Front Oncol* (2020) 10:581107. doi: 10.3389/ foncot.2020.581107

60. Ritchie D, Mileshkin L, Wall D, Bartholeyns J, Thompson M, Coverdale J, et al. In Vivo Tracking of Macrophage Activated Killer Cells to Sites of Metastatic Ovarian Carcinoma. *Cancer Immunol Immunother* (2007) 56:155–63. doi: 10.1007/s00262-006-0818-3

61. Burger M, Thiounn N, Denzing S, Kondas J, Benoit P, Chapado MS, et al. The Application of Adjuvant Autologous Antivascular Macrophage Cell Therapy vs. BCG in Non-Muscle Invasive Bladder Cancer: A Multicenter, Randomized Trial. *J Transl Med* (2010) 8:54. doi: 10.1186/1479-5876-8-54

62. Andreesen R, Scheibenbogen C, Brugger W, Krause S, Meerpohl HG, Leser GH, et al. Adaptive Transfer of Tumor Cytotoxic Macrophages Generated In Vitro From Circulating Blood Monocytes: A New Approach to Cancer Immunotherapy. *Cancer Res* (1990) 50:7450–6.

63. Klischinsky M, Ruella M, Sleathonio A, Lu XM, Best A, Zeeman M, et al. Human Chimeric Antigen Receptor Macrophage Initiating NK Cells for Cancer Immunotherapy. *Nat Biotechnol* (2020) 38:947–53. doi: 10.1038/s41587-020-0462-y

64. Kaczanowska S, Beury DW, Gopalan V, Tycko AK, Qin H, Clements ME, et al. Dysregulation of Chemokine/Chemokine Receptor Axes and NK Cell Tissue Localization During Diseases. *Front Immunol* (2016) 7:402. doi: 10.3389/fimmu.2016.00402

65. Felices M, Kodal B, Binderlie P, Kaminski MF, Cooley S, Weisdeif DJ, et al. Novel CD19-Targeted TriKE Restores NK Cell Function and Proliferative Capacity in CIL. *Blood Adv* (2019) 3:897–907. doi: 10.1182/bloodadvances.2018029371

66. Wang C, Cui A, Bukaeny M, Aung A, Pradhan D, Whittaker CA, et al. Reprogramming NK Cells and Macrophages via Combined Antibody and Cytokine Therapy Primes Tumors for Elimination by Checkpoint Blockade. *Cancer Res* (2021) 81:110021. doi: 10.1158/1078-0432.CCR-20-0432

67. Omer N, Nicholls W, Ruegg B, Souza-Fonseca-Guimaraes F, Rossi GR, et al. Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma. *Front Immunol* (2021) 12:791206. doi: 10.3389/fimmu.2021.791206
Immunotherapy and Diagnostic Marker Combined With NY-ESO-1. *Virochows Arch* (2017) 471:383–92. doi: 10.1007/s00428-017-2206-2

80. Majzner RG, Rietberg SP, Sottile O, Dong R, Vachharajani VT, Labanish L, et al. Tuning the Antigen Density Requirement for CAR-T Cell Activity. *Cancer Discov* (2020) 10:702–23. doi: 10.1158/2159-8290.CD-19-0945

81. Majzner RG, Mackall CL. Tumor Antigen Escape From CAR T-Cell Therapy. *Cancer Discov* (2018) 8:1219–26. doi: 10.1158/2159-8290.CD-18-0442

82. Wagner J, Wickman E, DeRenzo C, Gottschalk S. CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality? *Mol Ther* (2020) 28:2320–39. doi: 10.1016/j.ymthe.2020.09.015

Mo F, Pellerino A, Soffietti R, Ruda R. Blood-Brain Barrier in Brain Tumors: Biology and Clinical Relevance. *Int J Mol Sci* (2021) 22(23):12654. doi: 10.3390/ijms22312654

85. Louiillard E, Yang J, Bucrakma E, Wang J, Liu Y, Conboy C, et al. Targeting Tumor-Associated Macrophages and Granulocytic Myeloid-Derived Suppressor Cells Augments PD-1 Blockade in Cholangiocarcinoma. *J Clin Invest* (2020) 130:5380–96. doi: 10.1172/JCI137110

86. Liu Q, Yang C, Wang S, Shi D, Wei C, Song J, et al. Wnt5a-Induced M2 Polarization of Tumor-Associated Macrophages via IL-10 Promotes Colorectal Cancer Progression. *Cell Commun Signal* (2020) 18:51. doi: 10.1186/s12951-020-00557-2

87. Jeong H, Kim S, Hong BJ, Lee CJ, Lee SY, et al. Tumor-Associated Macrophages Enhance Tumor Hypoxia and Aerobic Glycolysis. *Cancer Res* (2019) 79:795–806. doi: 10.1158/0008-5472.CAN-18-2545

88. Liu G, Rui W, Zheng H, Huang D, Yu F, Zhang Y, et al. CXCR2-Modi

89. Priceman SJ, Tilakawardane D, Jeang B, Aguilar B, Murad JP, Park AK, et al. Deleting Etame AB, Diaz RJ, Smith CA, Mainprize TG, Hynynen K, Rutka JT. Blood-Brain Barrier Disruption in Neuro-Oncology: Strategies, Failures, and Effectively Targets HER2(+) Breast Cancer Metastasis to the Brain. *Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells for Therapeutic Delivery in Molecular Neurooncology. Focused Ultrasound Disruption of the Blood-Brain Barrier: A New Frontier of Hepatocellular Carcinoma.* *Cancer Res* (2019) 79:795–806. doi: 10.1158/0008-5472.CAN-18-2545

90. Liu G, Rui W, Zhao X, Lin X. Enhancing CAR-T Cell Efficacy in Solid Tumors by Targeting the Tumor Microenvironment. *Cell Mol Immunol* (2021) 18:1085–95. doi: 10.1016/j.cmi.2021.060655-2

91. Bourouh M, Palle J, Galy-Fauroix L, Termre M. Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment. *Front Immunol* (2021) 12:618837. doi: 10.3389/fimmu.2021.618837

92. Bocca P, Di Carlo E, Caruana I, Emonite L, Cilli M, De Angelis B, et al. Bevacizumab-Mediated Tumor Vascularite Remodelling Improves Tumor Infiltration and Antitumor Efficacy of GD2-CAR T Cells in a Human Neuroblastoma Preclinical Model. *Oncoimmunology* (2017) 7:e378843. doi: 10.2164/216240X2017.1378843

93. Shirimali RK, Yu Z, Theoret MR, Chimneysas D, Restifo NP, Rosenberg SA. Antiangiogenic Agents can Increase Lymphocyte Infiltration Into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer. *Cancer Res* (2010) 70:6171–80. doi: 10.1158/0008-5472.CAN-10-0153

94. Zhao R, Cui Y, Zheng Y, Li S, Lv J, Wu Q, et al. Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer. *Front Immunol* (2021) 12:660488. doi: 10.3389/fimmu.2021.660488

95. Caruana I, Savoldo B, Hoyos Y, Weber G, Liu H, Kim ES, et al. Heparanase Promotes Tumor Infiltration and Antitumor Activity of CAR-Redirected T Lymphocytes. *Nat Med* (2015) 21:524–9. doi: 10.1038/nm.3833

96. Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingamanno M, et al. 4-BBB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors. *Nat Med* (2021) 25:581–90. doi: 10.1038/nm.3838

97. Heitzeneder S, Bosse KR, Zhu Z, Zhihler D, Majzner RG, Radosovich MT, et al. GPC2-CAR T Cells Tuned for Low Antigen Density Mediate Potent Activity Against Neuroblastoma Without Toxicity. *Cancer Cell* (2022) 40:53–69. doi: 10.1016/j.ccell.2021.12.005

98. Lynn RC, Weber EW, Sottile O, Gennert D, Xu P, Good Z, et al. C-Jun Overexpression in CAR T Cells Induces Exhaustion Resistance. *Nature* (2019) 576:293–300. doi: 10.1038/s41586-019-1805-z

99. Liu G, Rui W, Zhao X, Lin X. Enhancing CAR-T Cell Efficacy in Solid Tumors by Targeting the Tumor Microenvironment. *Cell Mol Immunol* (2021) 18:1085–95. doi: 10.1016/j.cmi.2021.060655-2

Author Disclaimer: The content of this publication does not necessarily reflect the views of policies of the Department of Health and Human Services, nor does
mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Ligon, Wessel, Shah and Glod. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.